A pact with Dermelix Biotherapeutics to co-develop a cure for a rare pediatric genetic disease promises to generate vital funds for advancing EspeRare’s venture philanthropic model to tackle unmet life-threatening medical needs affecting children, the non-profit foundation’s CEO told Scrip.
Caroline Kant made the comments during an interview outlining EspeRare's pact with privately held Dermelix for co-development of the Swiss foundation's lead program, DMX-101, a novel in utero protein replacement therapy for the treatment of
